U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06973187) titled 'A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma' on May 07.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Lymphocytic Leukemia
Small Lymphocytic...